Press Releases

Smart Immune and CELLforCURE by SEQENS Partner to Industrialize SMART101 Clinical Batches Manufacturing

December 3, 2024

Smart Immune to Present ReSet-02 Phase I Preliminary Data and the Determination of the Recommended Dose at ASH 2024

November 5, 2024

Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials

October 23, 2024

Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial

Smart Immune appoints key new members to its Board of Directors

February 16, 2024

Rahim Fandi, M.D, PhD, joins Smart Immune as Chief Medical Officer

December 4, 2023